Ten63 Therapeutics
Proprietary drug discovery engine BEYOND, combining physics and AI in hyper-efficient search algorithms, to design potent chemistry against hard targets and exceed conventional therapeutic research, with a focus on oncology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | $15.9m | Series A | |
| Total Funding | 000k | ||
Related Content
Ten63 operates in the biotechnology sector, focusing on drug discovery through its proprietary AI-driven platform, BEYOND. The company targets previously undruggable chemical spaces, aiming to develop new therapeutics. Ten63 serves pharmaceutical companies and research institutions, providing them with innovative solutions to complex medical challenges. The business model revolves around leveraging advanced AI and physical models to identify potential drug candidates, which are then validated experimentally. Revenue is generated through partnerships, licensing agreements, and milestone payments from successful drug discoveries. The market for Ten63's services includes global pharmaceutical companies and biotech firms seeking cutting-edge drug discovery technologies.
Keywords: AI-driven, drug discovery, therapeutics, undruggable targets, biotechnology, pharmaceutical, research institutions, chemical space, licensing, partnerships.